Analyst Price Target is $60.45
▲ +39.10% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $60.45, with a high forecast of $70.00 and a low forecast of $50.00. The average price target represents a 39.10% upside from the last price of $43.46.
Current Consensus is
The current consensus among 12 contributing investment analysts is to buy stock in Accolade.
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.